• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

更新的透明细胞肾细胞癌患者在接受 VEGF 靶向治疗失败后的 EAU 指南。

Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.

机构信息

The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK.

Department of Urology, Ludwig-Maximilians University, Munich, Germany.

出版信息

Eur Urol. 2016 Jan;69(1):4-6. doi: 10.1016/j.eururo.2015.10.017. Epub 2015 Oct 24.

DOI:10.1016/j.eururo.2015.10.017
PMID:26508312
Abstract

The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.

摘要

欧洲泌尿外科学会肾癌指南已经更新，建议在 VEGF 靶向治疗失败一线或多线的患者中使用纳武利尤单抗和卡博替尼替代以前的标准治疗。

相似文献

1
Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.更新的透明细胞肾细胞癌患者在接受 VEGF 靶向治疗失败后的 EAU 指南。
Eur Urol. 2016 Jan;69(1):4-6. doi: 10.1016/j.eururo.2015.10.017. Epub 2015 Oct 24.
2
Cabozantinib and nivolumab for renal cell carcinoma.卡博替尼和纳武单抗用于治疗肾细胞癌。
Lancet Oncol. 2015 Nov;16(15):e531. doi: 10.1016/S1470-2045(15)00377-0. Epub 2015 Oct 5.
3
Cabozantinib: A Review in Advanced Renal Cell Carcinoma.卡博替尼：晚期肾细胞癌的研究进展。
Drugs. 2016 Dec;76(18):1771-1778. doi: 10.1007/s40265-016-0661-5.
4
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.卡博替尼对比依维莫司、纳武利尤单抗、阿昔替尼、索拉非尼及最佳支持治疗：晚期肾细胞癌二线治疗中无进展生存期和总生存期的网状Meta分析
PLoS One. 2017 Sep 8;12(9):e0184423. doi: 10.1371/journal.pone.0184423. eCollection 2017.
5
Cabozantinib for the treatment of renal cell carcinoma.卡博替尼用于治疗肾细胞癌。
Expert Opin Pharmacother. 2016 Dec;17(18):2499-2504. doi: 10.1080/14656566.2016.1258059. Epub 2016 Nov 22.
6
Kidney cancer: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.肾癌：晚期透明细胞肾细胞癌使用纳武利尤单抗是否可行？纳武利尤单抗和卡博替尼的疗效不佳，生存率低。
Nat Rev Clin Oncol. 2015 Nov;12(11):621. doi: 10.1038/nrclinonc.2015.178. Epub 2015 Oct 13.
7
Words of Wisdom. Re: Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma.智慧之言。关于：纳武单抗与依维莫司治疗晚期肾细胞癌的比较
Eur Urol. 2016 Apr;69(4):753-4. doi: 10.1016/j.eururo.2016.01.018. Epub 2016 Feb 18.
8
CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.晚期肾透明细胞癌（ccRCC）的CheckMate研究？纳武利尤单抗和卡博替尼的疗效较差。
Nat Rev Urol. 2015 Dec;12(12):651. doi: 10.1038/nrurol.2015.246. Epub 2015 Oct 13.
9
European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy.欧洲泌尿外科学会血管内皮生长因子受体靶向治疗耐药的肾透明细胞癌临床实践指南。
Eur Urol. 2016 Nov;70(5):705-706. doi: 10.1016/j.eururo.2016.06.009. Epub 2016 Jun 24.
10
Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.纳武利尤单抗对比卡博替尼：转移性肾细胞癌总生存期的比较
PLoS One. 2016 Jun 6;11(6):e0155389. doi: 10.1371/journal.pone.0155389. eCollection 2016.

引用本文的文献

1
Non-coding RNAs secreted by renal cancer include piR_004153 that promotes migration of mesenchymal stromal cells.肾癌分泌的非编码RNA包括促进间充质基质细胞迁移的piR_004153。
Cell Commun Signal. 2025 Jan 3;23(1):3. doi: 10.1186/s12964-024-02001-1.
2
Microbiome in urologic neoplasms: focusing on tumor immunity.泌尿系统肿瘤中的微生物群：聚焦肿瘤免疫
Front Immunol. 2024 Dec 5;15:1507355. doi: 10.3389/fimmu.2024.1507355. eCollection 2024.
3
Exploring the oncogenic potential of circSOD2 in clear cell renal cell carcinoma: a novel positive feedback loop.
探讨 circSOD2 在肾透明细胞癌中的致癌潜能：一个新的正反馈环。
J Transl Med. 2024 Jun 27;22(1):596. doi: 10.1186/s12967-024-05290-9.
4
Chinese herbal compound SanHuang decoction reverses axitinib resistance in ccRCC through regulating immune cell infiltration by affecting ADAMTS18 expression.中药复方三黄汤通过影响ADAMTS18表达调节免疫细胞浸润来逆转肾透明细胞癌对阿昔替尼的耐药性。
Am J Cancer Res. 2023 Jul 15;13(7):2841-2860. eCollection 2023.
5
Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma.全面分析 A12 代谢相关基因特征及其与透明细胞肾细胞癌肿瘤转移的关系。
BMC Cancer. 2023 Mar 23;23(1):264. doi: 10.1186/s12885-023-10740-6.
6
Evaluation of Apoptosis, Cell Proliferation and Cell Cycle Progression by Inactivation of the NEAT1 Long Noncoding RNA in a Renal Carcinoma Cell Line Using CRISPR/Cas9.利用CRISPR/Cas9技术使肾癌细胞系中的NEAT1长链非编码RNA失活，以此评估细胞凋亡、细胞增殖及细胞周期进程
Iran J Biotechnol. 2023 Jan 1;21(1):e3180. doi: 10.30498/ijb.2022.310632.3180. eCollection 2023 Jan.
7
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.在 SNiP-RCC 试验中，基因多态性对纳武利尤单抗治疗晚期肾细胞癌结局的影响。
Cancer Immunol Immunother. 2023 Jun;72(6):1903-1915. doi: 10.1007/s00262-023-03367-w. Epub 2023 Feb 2.
8
A novel thinking: DDR axis refines the classification of ccRCC with distinctive prognosis, multi omics landscape and management strategy.一种新的思维：DDR 轴以独特的预后、多组学景观和管理策略细化 ccRCC 的分类。
Front Public Health. 2022 Nov 21;10:1029509. doi: 10.3389/fpubh.2022.1029509. eCollection 2022.
9
Molecular mechanism of circRNAs in drug resistance in renal cell carcinoma.环状RNA在肾细胞癌耐药中的分子机制
Cancer Cell Int. 2022 Nov 24;22(1):369. doi: 10.1186/s12935-022-02790-w.
10
circCHST15 is a novel prognostic biomarker that promotes clear cell renal cell carcinoma cell proliferation and metastasis through the miR-125a-5p/EIF4EBP1 axis.环状 RNA CHST15 是一种新型的预后生物标志物，通过 miR-125a-5p/EIF4EBP1 轴促进肾透明细胞癌细胞的增殖和转移。
Mol Cancer. 2021 Dec 18;20(1):169. doi: 10.1186/s12943-021-01449-w.